1 BTC
=
- USD
Marinus Pharmaceuticals, Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Marinus Pharmaceuticals, Inc
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Market Statistics
Trading Metrics
How to Buy MRNS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MRNS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMonteverde & Associates PC, a top 50 securities class action firm, is investigating proposed mergers involving Vincerx Pharma, Vacasa, Marinus Pharmaceuticals, and Maiden Holdings. The firm is seeking to recover money for shareholders in these transactions.
Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the proposed sales of Marinus Pharmaceuticals, Vacasa, and the merger of Maiden Holdings with Kestrel Group LLC.
Marinus Pharmaceuticals has agreed to be acquired by Immedica Pharma for $151 million, a 48% premium over Marinus' last closing price. The deal will grant Immedica global rights to Marinus' rare neurology drug ZTALMY, boosting Immedica's rare disease portfolio and U.S. presence.
Marinus Pharmaceuticals (MRNS) is a micro-cap pharmaceutical company with mixed analyst sentiment. While some analysts see significant upside potential, others are more cautious. The company's primary drug, ganaxolone, has received FDA approval for a rare form of genetic epilepsy, but its revenue remains small. The company's future hinges on the success of its ongoing trials for treating Tuberous Sclerosis Complex, which could be a significant market opportunity.
The maternal mental health market is expected to grow rapidly due to the increasing incidence of conditions like postpartum depression and greater awareness of these issues. Notable companies in this market include Biogen, Sage Therapeutics, and Marinus Pharmaceuticals.
